Flutamide is a synthetic, non‑steroidal antiandrogen drug originally created in 1967 at Schering‑Plough as a potential bacteriostatic agent but was later found to block androgen receptors and inhibit the effects of male hormones; clinical research began around 1971, and it was first marketed in 1983 in countries like Germany and Chile before receiving U.S. FDA approval in 1989 for the treatment of metastatic prostate cancer, making it the first non‑steroidal antiandrogen used in clinical practice and later studied for other hormone‑related conditions.
BRAND NAMES
Eulexin: The primary brand name in the US and many international markets.
Cytomid: A widely available brand, particularly common in India (manufactured by Cipla).
Drogenil: Used in various international regions, including Europe.
Euflex: Another common trade name used in international markets.
Flucinom: A brand name used in several foreign markets.
